SEC Form 4 · accession 0001813798-26-000013
Vaxcyte, Inc. · PCVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jim Wassil
Officer — CHIEF OPERATING OFFICER
Period of report
Jul 1, 2026
Accepted (ET)
Jul 6, 2026 · 6:25 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001649094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 1, 2026 | M | 516 | $5.35 | A | 159,010 | D | |
| Common StockF2 | Jul 1, 2026 | S | 1,788 | $56.03 | D | 157,222 | D | |
| Common StockF3 | Jul 1, 2026 | S | 456 | $57.473 | D | 156,766 | D | |
| Common Stock | Jul 1, 2026 | S | 6 | $57.82 | D | 156,760 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $5.35 | Jul 1, 2026 | M | 516 | D | — | Apr 17, 2030 | Common Stock | 516 | 71,148 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
- F2The price reported is a weighted-average price. The shares were sold at prices ranging from $55.60 to $56.595. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The price reported is a weighted-average price. The shares were sold at prices ranging from $56.695 to $57.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Stock Option is fully vested and exercisable.